[go: up one dir, main page]

CY1105895T1 - Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης - Google Patents

Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης

Info

Publication number
CY1105895T1
CY1105895T1 CY20061101873T CY061101873T CY1105895T1 CY 1105895 T1 CY1105895 T1 CY 1105895T1 CY 20061101873 T CY20061101873 T CY 20061101873T CY 061101873 T CY061101873 T CY 061101873T CY 1105895 T1 CY1105895 T1 CY 1105895T1
Authority
CY
Cyprus
Prior art keywords
receptor
soluble
intepleukin
binder
chimeric protein
Prior art date
Application number
CY20061101873T
Other languages
English (en)
Inventor
Michel Revel
Judith Chebath
Tsvee Lapidot
Orit Kollet
Original Assignee
Yeda Research And Development Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105895(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Research And Development Company, Ltd. filed Critical Yeda Research And Development Company, Ltd.
Publication of CY1105895T1 publication Critical patent/CY1105895T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Παρέχονται χιμαιρικές πρωτεΐνες κατασκευασμένες από την σύντηξη της φυσικά απαντώμενης μορφής του διαλυτού υποδοχέα IL-6 και της IL-6 οι οποίες είναι χρήσιμες στην θεραπευτική αγωγή καρκίνου και ηπατικών ανωμαλιών, στην ενίσχυση μεταμόσχευσης μυελού οστών, και σε θεραπευτική αγωγή άλλων σχετιζόμενων με IL-6 καταστάσεων.
CY20061101873T 1997-07-10 2006-12-29 Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης CY1105895T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PCT/IL1998/000321 WO1999002552A2 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Publications (1)

Publication Number Publication Date
CY1105895T1 true CY1105895T1 (el) 2011-02-02

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101873T CY1105895T1 (el) 1997-07-10 2006-12-29 Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης

Country Status (26)

Country Link
US (2) US7198781B1 (el)
EP (1) EP0991661B1 (el)
JP (1) JP4402288B2 (el)
KR (1) KR100505172B1 (el)
CN (1) CN1185348C (el)
AR (1) AR013201A1 (el)
AT (1) ATE342915T1 (el)
AU (1) AU758161B2 (el)
BG (1) BG64680B1 (el)
BR (1) BR9812096B1 (el)
CA (1) CA2295936C (el)
CY (1) CY1105895T1 (el)
CZ (1) CZ302488B6 (el)
DE (1) DE69836217T2 (el)
DK (1) DK0991661T3 (el)
EA (1) EA004793B1 (el)
EE (1) EE05519B1 (el)
ES (1) ES2271999T3 (el)
HU (1) HU225855B1 (el)
IL (2) IL122818A0 (el)
NO (1) NO327397B1 (el)
NZ (1) NZ502139A (el)
PL (1) PL199212B1 (el)
PT (1) PT991661E (el)
SK (1) SK287039B6 (el)
WO (1) WO1999002552A2 (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
DE69941406D1 (de) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 Rezeptor IL-6-gekoppeltes Fusionsprotein
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
EP2295577A3 (en) * 1999-03-09 2012-08-08 ZymoGenetics, Inc. Human cytokine as ligand of the z-alpha receptor and uses thereof
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
CA2447632C (en) 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
CA2419954C (en) 2000-09-14 2012-01-03 Ares Trading S.A. Use of il-6r/il-6 chimera in huntington's disease
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
WO2003092579A2 (en) * 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
WO2007026353A2 (en) 2005-08-29 2007-03-08 Technion Research & Development Foundation Ltd. Media for culturing stem cells
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
ES2704401T3 (es) 2006-08-02 2019-03-18 Technion Res & Dev Foundation Métodos de expansión de células madre embrionarias en un cultivo en suspensión
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
JP5213075B2 (ja) * 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
JP2010535487A (ja) * 2007-08-03 2010-11-25 アステリオン・リミテッド 顆粒球コロニー刺激因子
CA2729747A1 (en) * 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Il6 immunotherapeutics
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
AU2010205782A1 (en) 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions
DK3633025T3 (da) 2009-11-12 2022-12-12 Technion Res & Dev Foundation Dyrkningsmedier, cellekulturer og metoder til dyrkning af pluripotente stamceller i en udifferentieret tilstand
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
SG10201800628QA (en) 2010-09-07 2018-02-27 Technion Res & Dev Foundation Novel Methods And Culture Media For Culturing Pluripotent Stem Cells
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
WO2015023505A1 (en) * 2013-08-12 2015-02-19 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6
CN116064563B (zh) * 2022-11-04 2025-11-11 广州达安基因股份有限公司 白细胞介素-6截短体的制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) * 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
UA74132C2 (uk) * 1997-12-19 2005-11-15 Апплайд Резеч Сістемз Арс Холдінг Н.В. КОМПЛЕКС, ЩО МІСТИТЬ IFN ТИПУ І І СУБОДИНИЦЮ РЕЦЕПТОРА ІНТЕРФЕРОНУ-<font face="Symbol">a</font>/<font face="Symbol">b</font> ЛЮДИНИ (IFNAR)

Also Published As

Publication number Publication date
CA2295936C (en) 2009-05-26
HK1031895A1 (en) 2001-06-29
NZ502139A (en) 2002-03-28
SK287039B6 (sk) 2009-10-07
AR013201A1 (es) 2000-12-13
KR100505172B1 (ko) 2005-08-03
NO327397B1 (no) 2009-06-22
PT991661E (pt) 2007-01-31
US7374912B2 (en) 2008-05-20
JP2001509371A (ja) 2001-07-24
EP0991661A2 (en) 2000-04-12
DE69836217T2 (de) 2007-08-23
HU225855B1 (en) 2007-11-28
DE69836217D1 (de) 2006-11-30
DK0991661T3 (da) 2007-02-05
BG64680B1 (bg) 2005-11-30
CZ200075A3 (cs) 2000-08-16
EA004793B1 (ru) 2004-08-26
CZ302488B6 (cs) 2011-06-15
SK62000A3 (en) 2000-07-11
BR9812096B1 (pt) 2011-09-06
EE05519B1 (et) 2012-02-15
US20070172455A1 (en) 2007-07-26
NO20000086L (no) 2000-03-08
WO1999002552A2 (en) 1999-01-21
EE200000012A (et) 2000-08-15
CA2295936A1 (en) 1999-01-21
CN1185348C (zh) 2005-01-19
US7198781B1 (en) 2007-04-03
EP0991661B1 (en) 2006-10-18
IL122818A0 (en) 1998-08-16
BR9812096A (pt) 2000-07-18
HUP0002426A2 (hu) 2000-11-28
HUP0002426A3 (en) 2003-01-28
NO20000086D0 (no) 2000-01-07
ATE342915T1 (de) 2006-11-15
JP4402288B2 (ja) 2010-01-20
AU758161B2 (en) 2003-03-20
KR20010021522A (ko) 2001-03-15
PL338002A1 (en) 2000-09-25
WO1999002552A3 (en) 1999-04-01
EA200000109A1 (ru) 2000-08-28
IL133972A (en) 2015-07-30
ES2271999T3 (es) 2007-04-16
BG104070A (en) 2000-11-30
CN1269835A (zh) 2000-10-11
PL199212B1 (pl) 2008-08-29
AU8127198A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
DK0971946T3 (da) Selektion af proteiner ved anvendelse af RNA-protein-fusioner
CY1115634T1 (el) Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
NO994998L (no) Fusjonsproteiner
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE69841607D1 (de) Menschliche Toll-Homologe
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
BR0009206A (pt) Isolamento e análise de proteina
ATE394484T1 (de) Smad 6 und dessen anwendungen
IL145689A0 (en) Methods
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ATE452650T1 (de) Transferrin-fusionsproteinbibliotheken
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
ATE366261T1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους